“…The mechanisms behind the possibility of using α-Gal for developing a single-antigen pan-vaccine for the control of infectious diseases caused by pathogens with this modification on their surface include pathogen opsonization by anti-α-Gal IgM/IgG-type antibodies and boosting the non-pathogen-specific protective immune mechanisms [ 10 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 ]. The immunization with α-Gal will increase the levels of the natural anti-α-Gal IgM/IgG-type antibodies produced in response to gut microbiota [ 15 ] and do not cause an increase in the IgE-type allergic response to tick saliva, which are involved in triggering the AGS [ 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 15 , 40 ]. Therefore, in principle, the α-Gal-based vaccines could be applied to all hosts that do not produce α-Gal, but the immune response could be affected by different factors including the ABO blood groups [ 17 ].…”